Comparison of outcomes between patients treated in UKALL2003/UKALL2011 and COG AALL0434/AALL1231
| . | . | CNS-1 . | CNS-2 . | CNS-3 . | P value∗ . |
|---|---|---|---|---|---|
| UKALL2003/UKALL2011 | Proportion | 87.4% | 6.9% | 5.7% | |
| 4-y CIR | 13.6% ± 1.7% | 25.9% ± 8.6% | 24.6% ± 10.1% | .241 | |
| 4-y EFS | 82.9% ± 1.6% | 74.1% ± 6.7% | 77.8% ± 8.0% | .623 | |
| 4-y OS | 88.6% ± 1.4% | 80.9% ± 6.1% | 91.8% ± 5.6% | .453 | |
| COG AALL0434/AALL1231 | Proportion | 72.3% | 20.4% | 7.3% | |
| 4-y CIR | 7.6% ± 0.7% | 9.9% ± 1.4% | 17.9% ± 3.1% | .0002 | |
| 4-y EFS | 85.1% ± 1.0% | 83.2 ± 2.0 | 71.8% ± 4.0% | .0004 | |
| 4-y OS | 90.1% ± 0.8% | 90.5% ± 1.6% | 82.7% ± 3.4% | .005 |
| . | . | CNS-1 . | CNS-2 . | CNS-3 . | P value∗ . |
|---|---|---|---|---|---|
| UKALL2003/UKALL2011 | Proportion | 87.4% | 6.9% | 5.7% | |
| 4-y CIR | 13.6% ± 1.7% | 25.9% ± 8.6% | 24.6% ± 10.1% | .241 | |
| 4-y EFS | 82.9% ± 1.6% | 74.1% ± 6.7% | 77.8% ± 8.0% | .623 | |
| 4-y OS | 88.6% ± 1.4% | 80.9% ± 6.1% | 91.8% ± 5.6% | .453 | |
| COG AALL0434/AALL1231 | Proportion | 72.3% | 20.4% | 7.3% | |
| 4-y CIR | 7.6% ± 0.7% | 9.9% ± 1.4% | 17.9% ± 3.1% | .0002 | |
| 4-y EFS | 85.1% ± 1.0% | 83.2 ± 2.0 | 71.8% ± 4.0% | .0004 | |
| 4-y OS | 90.1% ± 0.8% | 90.5% ± 1.6% | 82.7% ± 3.4% | .005 |
Survival rates are presented as rates ± standard errors.
CIR, cumulative incidence of relapse.
1-sided log-rank test.